Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer
作者:Hitesh K. Agarwal、Ahmed Khalil、Keisuke Ishita、Weilian Yang、Robin J. Nakkula、Lai-Chu Wu、Tehane Ali、Rohit Tiwari、Youngjoo Byun、Rolf F. Barth、Werner Tjarks
DOI:10.1016/j.ejmech.2015.05.042
日期:2015.7
amido-substituted carboranyl pyrimidine nucleoside analogs, designed as substrates and inhibitors of thymidine kinase 1 (TK1) for potential use in boron neutron capture therapy (BNCT) of cancer, was synthesized and evaluated in enzyme kinetic-, enzyme inhibition-, metabolomic-, and biodistribution studies. One of these 2nd generation carboranyl pyrimidine nucleoside analogs (YB18A [3]), having an amino group directly
合成了十六个第二代氨基和酰胺基取代的碳硼烷基嘧啶核苷类似物的文库,并设计为可用于癌症的硼中子捕获疗法(BNCT)的胸苷激酶1(TK1)的底物和抑制剂,并通过酶动力学进行了评估-,酶抑制-,代谢组学和生物分布研究。这些第二代碳硼烷基嘧啶核苷类似物(YB18A [ 3 ])中的一个,氨基直接与通过乙烯间隔基束缚在胸腺嘧啶3位上的间甲碳氢化合物笼相连,具有约3-4倍的底物hTK1和抑制剂比N5 - 2OH(2-),是第一代碳硼烷基嘧啶核苷类似物。既2和3似乎是5'-单磷酸化在TK1(+)细胞RG2,无论在体外和体内。对携带脑内RG2神经胶质瘤的大鼠进行生物分布研究后,选择性摄取了3种肿瘤,瘤内浓度大约是2种的4倍。获得的结果大大提高了对TK1和碳硼烷基嘧啶核苷类似物之间结合相互作用的理解,并将深刻影响这些试剂的未来设计策略。